In this review:
PTEN loss: a prognostic marker for mCRPC?
Custirsen: no survival benefit in mCRPC
MFS: a surrogate for OS in localised prostate cancer
Alisertib shows activity in neuroendocrine prostate cancer
Enzalutamide: durable responses in mCRPC
Pembrolizumab active in pretreated, advanced PD-L1+ disease
ADT + docetaxel: clinical benefit in high-volume disease
AR-V7: no link with primary resistance to enzalutamide
Please login below to download this issue (PDF)